Product
LSC2
1 clinical trial
1 indication
Indication
Limbal Stem Cell DeficiencyClinical trial
An Interventional, Open-label, Multicenter Phase I/IIa Clinical Trial to Investigate the Safety and Efficacy of Ascending Doses of Allogeneic ABCB5-positive Limbal Stem Cells (LSC2) for the Treatment of Limbal Stem Cell Deficiency (LSCD)Status: Active (not recruiting), Estimated PCD: 2023-09-01